Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer

Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT07831330 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 59 participants, started 2026-09-05 and due to reach its primary completion in 2029-01-31. Interventions recorded: Albumin-bound Paclitaxel (II) + Gemcitabine. Conditions listed: Metastatic Pancreatic Adenocarcinoma; Albumin-bound Paclitaxel (II); Gemcitabine; First-Line. Primary outcome: Objective Response Rate(ORR). Pancreatic eligibility wording from the registry: "Histopathologically or cytologically confirmed metastatic pancreatic adenocarcinoma ; 3". No results are recorded here; the registry entry is the source.